MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573409 | Name: Rasagiline
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rasagiline is a selective and irreversible propargylamine inhibitor of monoamine oxidase type-B (MAO-B) that is not metabolized to amphetamine derivatives. Rasagiline exhibits neuroprotective and antiapoptotic activity against ischemia and several neurotoxins, including SIN-1, MPTP, 6-hydroxydopamine, and N-methyl-(R)-salsolinol.

Chemical Structure

Rasagiline
Rasagiline
CAS#136236-51-6

Theoretical Analysis

MedKoo Cat#: 573409

Name: Rasagiline

CAS#: 136236-51-6

Chemical Formula: C12H13N

Exact Mass: 171.1048

Molecular Weight: 171.24

Elemental Analysis: C, 84.17; H, 7.65; N, 8.18

Price and Availability

Size Price Availability Quantity
10mg USD 205.00
25mg USD 325.00
50mg USD 500.00
100mg USD 900.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Azilect, HSDB 7699, Rasagiline, TV 1030, TV-1030
IUPAC/Chemical Name
1-Indanamine, N-2-propynyl-, (R)-
InChi Key
RUOKEQAAGRXIBM-GFCCVEGCSA-N
InChi Code
1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
SMILES Code
C#CCN[C@@H]1CCc2c1cccc2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO (need ultrasonic)
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Rasagiline is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.
In vitro activity:
Compound 6j (a rasagiline-clorgyline hybrid) displayed low toxicity and good neuroprotective effects in SH-SY5Y cell assay. These results indicated that compound 6j was an effective and promising multitarget agent against Alzheimer's disease. Reference: Eur J Med Chem. 2020 Sep 15;202:112475. https://pubmed.ncbi.nlm.nih.gov/32652406/
In vivo activity:
This meta-analysis highlights the superiority of rasagiline/levodopa in improving motor and nonmotor symptoms of Parkinson's disease, with a similar safety profile to that of levodopa in Parkinson's disease with motor fluctuations. Reference: Parkinsons Dis. 2022 Aug 30;2022:4216452. https://pubmed.ncbi.nlm.nih.gov/36081594/
Solvent mg/mL mM
Solubility
DMSO (ultrasonic) 100.0 583.98
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 171.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Xie SS, Liu J, Tang C, Pang C, Li Q, Qin Y, Nong X, Zhang Z, Guo J, Cheng M, Tang W, Liang N, Jiang N. Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease. Eur J Med Chem. 2020 Sep 15;202:112475. doi: 10.1016/j.ejmech.2020.112475. Epub 2020 Jun 30. PMID: 32652406. 2. Vale N, Alves C, Sharma V, Lázaro DF, Silva S, Gomes P, Outeiro TF. A new MAP-Rasagiline conjugate reduces α-synuclein inclusion formation in a cell model. Pharmacol Rep. 2020 Apr;72(2):456-464. doi: 10.1007/s43440-019-00032-x. Epub 2020 Jan 15. PMID: 32048262. 3. Kano O, Tsuda H, Hayashi A, Arai M. Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis. Parkinsons Dis. 2022 Aug 30;2022:4216452. doi: 10.1155/2022/4216452. PMID: 36081594; PMCID: PMC9448622. 4. Oka H, Sengoku R, Nakahara A, Yamazaki M. Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson's disease. Clin Park Relat Disord. 2021 Dec 13;6:100124. doi: 10.1016/j.prdoa.2021.100124. PMID: 34977548; PMCID: PMC8689235.
In vitro protocol:
1. Xie SS, Liu J, Tang C, Pang C, Li Q, Qin Y, Nong X, Zhang Z, Guo J, Cheng M, Tang W, Liang N, Jiang N. Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease. Eur J Med Chem. 2020 Sep 15;202:112475. doi: 10.1016/j.ejmech.2020.112475. Epub 2020 Jun 30. PMID: 32652406. 2. Vale N, Alves C, Sharma V, Lázaro DF, Silva S, Gomes P, Outeiro TF. A new MAP-Rasagiline conjugate reduces α-synuclein inclusion formation in a cell model. Pharmacol Rep. 2020 Apr;72(2):456-464. doi: 10.1007/s43440-019-00032-x. Epub 2020 Jan 15. PMID: 32048262.
In vivo protocol:
1. Kano O, Tsuda H, Hayashi A, Arai M. Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis. Parkinsons Dis. 2022 Aug 30;2022:4216452. doi: 10.1155/2022/4216452. PMID: 36081594; PMCID: PMC9448622. 2. Oka H, Sengoku R, Nakahara A, Yamazaki M. Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson's disease. Clin Park Relat Disord. 2021 Dec 13;6:100124. doi: 10.1016/j.prdoa.2021.100124. PMID: 34977548; PMCID: PMC8689235.
1: Singh A, Sinha S, Singh NK. Dietary Natural Flavonoids: Intervention for MAO-B Against Parkinson's Disease. Chem Biol Drug Des. 2024 Sep;104(3):e14619. doi: 10.1111/cbdd.14619. PMID: 39223743. 2: Pandur E, Major B, Rák T, Sipos K, Csutak A, Horváth G. Linalool and Geraniol Defend Neurons from Oxidative Stress, Inflammation, and Iron Accumulation in In Vitro Parkinson's Models. Antioxidants (Basel). 2024 Jul 29;13(8):917. doi: 10.3390/antiox13080917. PMID: 39199163; PMCID: PMC11351228. 3: Bovenzi R, Conti M, Pierantozzi M, Testone G, Fernandes M, Manfredi N, Schirinzi T, Cerroni R, Mercuri NB, Stefani A, Liguori C. Safinamide effect on sleep architecture of motor fluctuating Parkinson's disease patients: A polysomnographic rasagiline-controlled study. Parkinsonism Relat Disord. 2024 Aug 13;127:107103. doi: 10.1016/j.parkreldis.2024.107103. Epub ahead of print. PMID: 39154406. 4: Abu-Hassan AA, Mahdi WA, Alshehri S, El Hamd MA. Efficient application of Pyrosin B for nano-gram level assay of antiparkinsonian medication, rasagiline: Evaluation of tablets and content uniformity. Luminescence. 2024 Aug;39(8):e4853. doi: 10.1002/bio.4853. PMID: 39103189. 5: Lecht S, Lahiani A, Klazas M, Naamneh MS, Rubin L, Dong J, Zheng W, Lazarovici P. Rasagiline Exerts Neuroprotection towards Oxygen-Glucose- Deprivation/Reoxygenation-Induced GAPDH-Mediated Cell Death by Activating Akt/Nrf2 Signaling. Biomedicines. 2024 Jul 17;12(7):1592. doi: 10.3390/biomedicines12071592. PMID: 39062165; PMCID: PMC11275171. 6: Matthews DC, Kinney JW, Ritter A, Andrews RD, Toledano Strom EN, Lukic AS, Koenig LN, Revta C, Fillit HM, Zhong K, Tousi B, Leverenz JB, Feldman HH, Cummings J. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients. Alzheimers Dement (N Y). 2024 Jul 9;10(3):e12490. doi: 10.1002/trc2.12490. PMID: 38988416; PMCID: PMC11233274. 7: Liu J, Li L, He S, Zheng X, Zhu D, Kong G, Li P. EXPLORING THE PROGNOSTIC NECROPTOSIS-RELATED GENES AND UNDERLYING MECHANISM IN SEPSIS USING BIOINFORMATICS. Shock. 2024 Sep 1;62(3):363-374. doi: 10.1097/SHK.0000000000002414. Epub 2024 Jun 24. PMID: 38920136. 8: Zhao H, Ding R, Han J. Ginsenoside Rh4 Facilitates the Sensitivity of Renal Cell Carcinoma to Ferroptosis via the NRF2 Pathway. Arch Esp Urol. 2024 Mar;77(2):119-128. doi: 10.56434/j.arch.esp.urol.20247702.16. PMID: 38583003. 9: Fan Y, Wang J, Jian J, Wen Y, Li J, Tian H, Crommen J, Bi W, Zhang T, Jiang Z. High-throughput discovery of highly selective reversible hMAO-B inhibitors based on at-line nanofractionation. Acta Pharm Sin B. 2024 Apr;14(4):1772-1786. doi: 10.1016/j.apsb.2024.01.020. Epub 2024 Feb 6. PMID: 38572096; PMCID: PMC10985270. 10: Patel R, Patel M, Solanki R, Khunt D. Trace level quantification of N-nitrosorasagiline in rasagiline tablets by LC-TQ-MS/MS. Ann Pharm Fr. 2024 Sep;82(5):771-779. doi: 10.1016/j.pharma.2024.03.006. Epub 2024 Mar 27. PMID: 38548223. 11: Abu-Hassan AA, Shaaban Mohammed B, Mahdi WA, Alshehri S, El Hamd MA. Synergistic utility of NBD-Cl fluorogenic loading activity and salting-out assisted liquid-liquid extraction as sample pretreatment in rasagiline tracking in different matrices. Spectrochim Acta A Mol Biomol Spectrosc. 2024 May 15;313:124168. doi: 10.1016/j.saa.2024.124168. Epub 2024 Mar 16. PMID: 38513420. 12: Kryl'skii ED, Razuvaev GA, Popova TN, Oleinik SA, Medvedeva SM, Shikhaliev KS. 6-Hydroxy-2,2,4-trimethyl-1,2,3,4-tetrahydroquinoline Demonstrates Neuroprotective Properties in Experimental Parkinson's Disease by Enhancing the Antioxidant System, Normalising Chaperone Activity and Suppressing Apoptosis. Neurochem Res. 2024 May;49(5):1387-1405. doi: 10.1007/s11064-024-04125-9. Epub 2024 Mar 19. PMID: 38502411. 13: Sasikumar DSN, Thiruselvam P, Sundararajan V, Ravindran R, Gunasekaran S, Madathil D, Kaliamurthi S, Peslherbe GH, Selvaraj G, Sudhakaran SL. Insights into dietary phytochemicals targeting Parkinson's disease key genes and pathways: A network pharmacology approach. Comput Biol Med. 2024 Apr;172:108195. doi: 10.1016/j.compbiomed.2024.108195. Epub 2024 Feb 20. PMID: 38460310. 14: Koner S, Luo S. Projection-based two-sample inference for sparsely observed multivariate functional data. Biostatistics. 2024 Feb 27:kxae004. doi: 10.1093/biostatistics/kxae004. Epub ahead of print. PMID: 38413051. 15: Albertini C, Petralla S, Massenzio F, Monti B, Rizzardi N, Bergamini C, Uliassi E, Borges F, Chavarria D, Fricker G, Goettert M, Kronenberger T, Gehringer M, Laufer S, Bolognesi ML. Targeting Lewy body dementia with neflamapimod-rasagiline hybrids. Arch Pharm (Weinheim). 2024 Jun;357(6):e2300525. doi: 10.1002/ardp.202300525. Epub 2024 Feb 27. PMID: 38412454. 16: Li X, Zhang W, Xing Z, Hu S, Zhang G, Wang T, Wang T, Fan Q, Chen G, Cheng J, Jiang X, Cai R. Targeting SIRT3 sensitizes glioblastoma to ferroptosis by promoting mitophagy and inhibiting SLC7A11. Cell Death Dis. 2024 Feb 23;15(2):168. doi: 10.1038/s41419-024-06558-0. PMID: 38395990; PMCID: PMC10891132. 17: Cunha-Oliveira T, Montezinho L, Simões RF, Carvalho M, Ferreiro E, Silva FSG. Mitochondria: A Promising Convergent Target for the Treatment of Amyotrophic Lateral Sclerosis. Cells. 2024 Jan 29;13(3):248. doi: 10.3390/cells13030248. PMID: 38334639; PMCID: PMC10854804. 18: Seppänen P, Forsberg MM, Tiihonen M, Laitinen H, Beal S, Dorman DC. A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson's Disease. Parkinsons Dis. 2024 Jan 16;2024:8448584. doi: 10.1155/2024/8448584. PMID: 38264500; PMCID: PMC10805557. 19: Zhang T, Wang MY, Wang GD, Lv QY, Huang YQ, Zhang P, Wang W, Zhang Y, Bai YP, Guo LQ. Metformin improves nonalcoholic fatty liver disease in db/db mice by inhibiting ferroptosis. Eur J Pharmacol. 2024 Mar 5;966:176341. doi: 10.1016/j.ejphar.2024.176341. Epub 2024 Jan 18. PMID: 38244761. 20: Schuster J, Dreyhaupt J, Mönkemöller K, Dupuis L, Dieterlé S, Weishaupt JH, Kassubek J, Petri S, Meyer T, Grosskreutz J, Schrank B, Boentert M, Emmer A, Hermann A, Zeller D, Prudlo J, Winkler AS, Grehl T, Heneka MT, Johannesen S, Göricke B, Witzel S, Dorst J, Ludolph AC; RAS-ALS Study Group. In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis. Eur J Neurol. 2024 Apr;31(4):e16204. doi: 10.1111/ene.16204. Epub 2024 Jan 19. PMID: 38240416; PMCID: PMC11235627.